Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (5 d 13:12 ago) – Posting: # 24336
Views: 201

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?

Edit: Category changed; see also this post #1. [Helmut]
—
Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,362 posts in 4,906 threads, 1,678 registered users;
116 visitors (0 registered, 116 guests [including 7 identified bots]).
Forum time: 13:09 CET (Europe/Vienna)

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5